Good news on an ex-dividend day .....
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.
· Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
· Full data to be presented at 2024 American Society of Hematology Annual Meeting in December
· Data to be shared with health authorities to support regulatory filings |
Why? It's cheap, and I hope it powers up to a normal valuation and stays as a strong British company |
That is very unlikely |
Hope some company takes GSK over |
IN @ 1367.247 .... ;0) |
Last xd coincided with good news and the shares ended up on the day. |
15p xd tomorrow, usually drops more than 15p unless strong FT100, IMO |
Gsk not even going north before xdI am waiting for it to fall a bit further to top up. |
Nigel Farage holds 2 passports, British and German.
I bought GSK yesterday. |
how can we have a mp who has two passports which tells you he is not committed to this country and that is lammy whom i find him totally unsuitable to represent this country whats left of it.. |
Self-fulfilling .... |
He's better than that. Trump loves us |
He will like the U.K. if that idiot Lammy goes. |
trump loves the UK. EU not so much. We'll be fine |
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.
The British Big Pharma will take on responsibility for Vesalius’ small molecule, with the option to move forward Vesalius-identified intervention point programs in Parkinson’s and another unnamed neurodegenerative condition, according to a Nov. 12 release. GSK will retain rights over all development and commercial activities.
In return, Vesalius will receive $80 million in upfront and equity payments and has the chance to make up to $570 million in potential milestones for the preclinical small molecule program, plus royalties.
The Cambridge, Massachusetts-based biotech could also bring in additional biobucks and royalties tied to each new intervention point resulting from the deal. The partners did not disclose the potential total value of the entire pact. |
Not GSK, all UK stocksEasiest market to short. Even zimbabwe has a more growth focused gov than starmer and coNo dbt reeves will start introducing a ban on shorting |
Not much interest in buying before the divi Gsk so unloved at the moment.I am holding firm and may top up at some point. Sitting on my hands right now. |
Jefferies cuts to hold from buy. Target price to 1,525p from 2,000p |
 GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in October that will see claims settled for a total of $2.2bn (£1.68bn). While this overshadowed the results, the pharmaceutical company was able to reaffirm its guidance for the year. Management expects turnover growth of 7-9 per cent; core operating profit growth of 11-13 per cent and core earnings per share (EPS) growth of 10-12 per cent, with GSK expected to deliver broadly around the middle of the existing ranges. The third-quarter performance was generally acceptable, with turnover growing by 2 per cent to £8bn, with a notable increase in core EPS, which was up 5 per cent to 49.7p. The core operating profit also increased by 5 per cent to £2.76bn, which excludes the impact of large one-off costs. Once these are included then reported quarterly operating profits dropped by 86 per cent. Analysts were generally sceptical about the company's vaccines performance. Sheena Berry, healthcare equity analyst at Quilter Cheviot noted: "The performance of key vaccines was underwhelming. Shingrix and Arexvy saw declines of 7 per cent and 72 per cent, respectively, largely due to changes in ACIP [Advisory Committee on Immunization Practices, part of the CDC] guidelines and the prioritisation of Covid vaccines in the US".Chief executive Emma Walmsley said: "Our pipeline continues to strengthen, with 11 positive phase III trials reported so far this year and we are currently planning launches for five major new product approval opportunities next year... All this means we are on track to deliver our 2024 guidance, and we are even more confident in our 2026 and 2031 outlooks." |
Further falls to come |
Dartboard and blindfold |
Barclays said 1725p in May ...... short-termism with this 'broker'? |
Barclays cuts target price to 1450p from 1550p |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
